phenylalanine has been researched along with ajm300 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andou, A; Dohi, T; Eda, H; Ejima, C; Kageyama, S; Miyazawa, T; Nakayama, A; Sugiura, T | 1 |
| Papadakis, KA; Saruta, M | 1 |
| Kanai, T; Mizuno, S; Naganuma, M; Nanki, K; Sugimoto, S | 1 |
| Coskun, M; Nielsen, OH; Vermeire, S | 1 |
| Fukase, H; Furuie, H; Ikeda, N; Kajioka, T; Oikawa, I | 2 |
| Cheng, Y; Hao, J; Lai, Y; Liang, X; Niu, C | 1 |
| Hibi, T; Hirai, F; Ishida, T; Ishiguro, Y; Kajioka, T; Kanke, K; Kishida, S; Kobayashi, K; Matsuoka, K; Miura, Y; Mizusawa, H; Nakajima, K; Ohmori, T; Ohta, A; Watanabe, K; Watanabe, M | 1 |
| Dhillon, S | 1 |
| Goto, A; Ikeda, N; Izumi-Nakaseko, H; Kambayashi, R; Kumagai, Y; Matsuda, K; Matsumoto, A; Oikawa, I; Sugiyama, A; Takei, Y | 1 |
4 review(s) available for phenylalanine and ajm300
| Article | Year |
|---|---|
Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Adhesion Molecules; Gastrointestinal Agents; Humans; Immunoglobulins; Inflammatory Bowel Diseases; Integrins; Intercellular Adhesion Molecule-1; Mucoproteins; Natalizumab; Phenylalanine; Phosphorothioate Oligonucleotides; Quinazolinones; Receptors, CCR; Sulfonamides | 2014 |
Recent trends and future directions for the medical treatment of ulcerative colitis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Budesonide; Calcineurin Inhibitors; Colitis, Ulcerative; Drug Therapy, Combination; Drugs, Chinese Herbal; Forecasting; Gastrointestinal Agents; Glucocorticoids; Humans; Phenylalanine; Piperidines; Pyrimidines; Pyrroles; Quinazolinones; Tumor Necrosis Factor-alpha | 2016 |
Novel Targeted Therapies for Inflammatory Bowel Disease.
Topics: Animals; Antibodies, Monoclonal, Humanized; Humans; Indans; Inflammatory Bowel Diseases; Interleukin-23; Interleukin-6; Janus Kinase 1; Oligonucleotides, Antisense; Oxadiazoles; Phenylalanine; Precision Medicine; Quinazolinones; Quinolones; Smad7 Protein | 2017 |
Carotegrast Methyl: First Approval.
Topics: Cell Adhesion; Colitis, Ulcerative; Endothelial Cells; Humans; Integrin alpha4; Integrins; Phenylalanine; Quinazolinones | 2022 |
4 trial(s) available for phenylalanine and ajm300
| Article | Year |
|---|---|
AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Integrins; Lymphocytes; Male; Phenylalanine; Quinazolinones | 2020 |
Food Effect on a Single High Dose of Carotegrast Methyl, an Oral Antagonist of α4-Integrin, in Healthy Male Subjects: A Randomised, Placebo-Controlled, Double-Blind Study.
Topics: Administration, Oral; Adult; Area Under Curve; Cross-Over Studies; Double-Blind Method; Fasting; Food-Drug Interactions; Humans; Integrin alpha4; Male; Phenylalanine; Quinazolines; Quinazolinones; Young Adult | 2020 |
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Topics: Colitis, Ulcerative; Humans; Induction Chemotherapy; Integrin alpha4; Mesalamine; Nasopharyngitis; Phenylalanine; Quinazolinones; Treatment Outcome | 2022 |
Appraisal of ICH E14/S7B Q&As adopted in February 2022 using thorough QT/QTc study data for α4-integrin antagonist carotegrast methyl in Japanese healthy subjects.
Topics: Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Fluoroquinolones; Healthy Volunteers; Heart Rate; Humans; Integrin alpha4; Japan; Long QT Syndrome; Moxifloxacin; Phenylalanine; Quinazolinones | 2022 |
2 other study(ies) available for phenylalanine and ajm300
| Article | Year |
|---|---|
Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Biopsy, Needle; Cell Adhesion Molecules; Colitis, Ulcerative; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Immunohistochemistry; Integrin alpha4; Male; Mice; Mice, Inbred BALB C; Phenylalanine; Quinazolinones; Random Allocation; Reference Values | 2013 |
Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys.
Topics: Animals; Area Under Curve; Benzophenones; Bromobenzenes; Drug Interactions; Hepatobiliary Elimination; Liver; Macaca fascicularis; Male; Models, Animal; Models, Biological; Organic Anion Transporters; Phenylalanine; Quinazolinones; Rosuvastatin Calcium | 2021 |